Cancer treatment is increasingly moving away from a one-size-fits-all approach. As medical science advances, researchers are focusing on therapies tailored to each individual patient, aiming to improve outcomes while reducing the risk of the disease returning.
New findings presented at the American Society of Clinical Oncology (ASCO) Annual Meeting suggest that a personalized mRNA vaccine could become an important tool in the fight against melanoma.
Researchers reported encouraging long-term results when the experimental vaccine was used alongside the immunotherapy drug Keytruda, reports Medical News Today.
Built for each patient
Unlike traditional treatments, the vaccine is created using genetic information taken from a patient's own tumor. Scientists analyze the cancer's unique mutations and design a vaccine intended to help the immune system identify and destroy remaining cancer cells.
Also read: These foods may help keep your brain sharp as you age
The study involved 157 patients with high-risk melanoma who had previously undergone surgery. Participants received either standard treatment with Keytruda or a combination of Keytruda and the personalized vaccine.
Results stand out
After five years of follow-up, researchers found a significant difference between the two groups. Patients receiving the combination therapy experienced a 59% lower risk of the cancer spreading to distant organs compared with those receiving Keytruda alone.
The data also showed higher overall survival rates among patients who received the personalized vaccine. Researchers believe the findings indicate that the immune response generated by the treatment may remain active for years after administration.
What's next?
Despite the promising results, experts caution that larger studies are still needed before the treatment can become part of routine clinical care. A phase 3 trial is already underway to confirm the findings in a broader patient population.
Also read: A child’s birth month may affect their risk of getting the flu
The manufacturing process also remains a challenge, as every vaccine must be custom-made from an individual patient's tumor sample. Even so, researchers see the latest results as a strong indication that personalized cancer vaccines may play a significant role in the future of oncology.
Sources: Medical News Today
Also read: Dermatologists: Your position in the shower may affect your skin health